Observational analysis reveals enhanced safety and effectiveness of dupilumab in atopic dermatitis patients, indicating substantial benefits for those with food allergies.
Real-world evidence consistently confirms the high effectiveness, favorable safety profile, and long-term treatment durability of dupilumab across various patient subgroups, including children, elderly, and patients with different underlying immune and genetic profiles. Additionally, dupilumab has demonstrated beneficial effects in patients with comorbid asthma and food allergies. Emerging data further support its potential safety during pregnancy, breastfeeding, and (non-)live vaccinations. Dose tapering is often successful and lowers the socio-economic impact of dupilumab.
No takes yet. Share an insight, caveat, or question.
Bakker et al. (2025) studied this question.